Evidence map›Paper›PMID 27062563›Full record

ArticleBiological psychiatry2016

Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.

Zhen Ren, Horia Pribiag, Sarah J Jefferson, Matthew Shorey, Thomas Fuchs, David Stellwagen, Bernhard Luscher

Open access · hybridAbstract read
In one paragraph

Article in Biological psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.

  1. Guideline
  2. Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2020
    Trial
  3. Article
  4. Ketamine and Evolving Neuroplasticity.Clinical drug investigation · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. GABADrug design, development and therapy · 2026
    Review
  10. Article
  11. Article
  12. Concerted elevations of cortical and striatal glutamate and GABA in antipsychotic-free individuals at clinical high-risk for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  13. Article
  14. Article
  15. Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  16. Article
  17. The involvement of KTranslational psychiatry · 2024
    Review
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Zhen RenDepartments of Biology, Pennsylvania State University, University Park, Pennsylvania.
Horia PribiagCenter for Research in Neuroscience (HP, DS), McGill University, Montreal General Hospital, Montreal, Quebec, Canada.
Sarah J JeffersonDepartments of Biology, Pennsylvania State University, University Park, Pennsylvania.
Matthew ShoreyDepartments of Biology, Pennsylvania State University, University Park, Pennsylvania.
Thomas FuchsDepartments of Biology, Pennsylvania State University, University Park, Pennsylvania.
David StellwagenCenter for Research in Neuroscience (HP, DS), McGill University, Montreal General Hospital, Montreal, Quebec, Canada.
Bernhard LuscherDepartments of Biology, Pennsylvania State University, University Park, Pennsylvania; Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania; Center for Molecular Investigation of Neurological Disorders, Pennsylvania State University, University Park, Pennsylvania. Electronic address: BXL25@psu.edu.
Pennsylvania State University · USMcGill University · CAMontreal General Hospital · CA

Funding

GABAergic Control of Depression Related Brain StatesR01MH099851 · NIMH · PENNSYLVANIA STATE UNIVERSITY, THE · PI LUSCHER, BERNHARD · 2013 to 2019
$3.2M
Use of a mouse model of anxious depression to assess the safety of pediatric antiRC1MH089111 · NIMH · PENNSYLVANIA STATE UNIVERSITY, THE · PI LUSCHER, BERNHARD · 2009 to 2010
$828k
CIHR MOP136881NIMH NIH HHS R01 MH099851NIMH NIH HHS RC1 MH089111
6 · The paper itself

Abstract

backgroundMajor depressive disorder is increasingly recognized to involve functional deficits in both gamma-aminobutyric acid (GABA)ergic and glutamatergic synaptic transmission. To elucidate the relationship between these phenotypes, we used GABAA receptor γ2 subunit heterozygous (γ2(+/-)) mice, which we previously characterized as a model animal with construct, face, and predictive validity for major depressive disorder.

methodsTo assess possible consequences of GABAergic deficits on glutamatergic transmission, we quantitated the cell surface expression of N-methyl-D-aspartate (NMDA)-type and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors and the function of synapses in the hippocampus and medial prefrontal cortex of γ2(+/-) mice. We also analyzed the effects of an acute dose of the experimental antidepressant ketamine on all these parameters in γ2(+/-) versus wild-type mice.

resultsModest defects in GABAergic synaptic transmission of γ2(+/-) mice resulted in a strikingly prominent homeostatic-like reduction in the cell surface expression of NMDA-type and AMPA-type glutamate receptors, along with prominent functional impairment of glutamatergic synapses in the hippocampus and medial prefrontal cortex. A single subanesthetic dose of ketamine normalized glutamate receptor expression and synaptic function of γ2(+/-) mice to wild-type levels for a prolonged period, along with antidepressant-like behavioral consequences selectively in γ2(+/-) mice. The GABAergic synapses of γ2(+/-) mice were potentiated by ketamine in parallel but only in the medial prefrontal cortex.

conclusionsDepressive-like brain states that are caused by GABAergic deficits involve a homeostatic-like reduction of glutamatergic transmission that is reversible by an acute, subanesthetic dose of ketamine, along with regionally selective potentiation of GABAergic synapses. The data merge the GABAergic and glutamatergic deficit hypotheses of major depressive disorder.

Indexed as

AnimalsBehavior, AnimalDown-Regulationgamma-Aminobutyric AcidGlutamic AcidHippocampusHomeostasisKetamineMajor Depressive DisorderMicePrefrontal CortexReceptors, AMPAReceptors, GABA-AReceptors, N-Methyl-D-AspartateSynapsesGabrg2 protein, mousegamma-Aminobutyric AcidGlutamic AcidKetamineReceptors, AMPAReceptors, GABA-AReceptors, N-Methyl-D-AspartateAntidepressant drug mechanismsGABAGlutamateHomeostatic synaptic plasticityMajor depressive disorderNeuroligin

Identifiers

PMID27062563
PMCPMC4983262
OpenAlexW2315792699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.